Christopher David Ozeroff - Dec 14, 2021 Form 4 Insider Report for ARCA biopharma, Inc. (ABIO)

Signature
/s/ C. Jeffrey Dekker, Attorney-in-Fact
Stock symbol
ABIO
Transactions as of
Dec 14, 2021
Transactions value $
$0
Form type
4
Date filed
12/16/2021, 03:33 PM
Previous filing
Nov 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABIO Common Stock 51K Dec 14, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABIO Stock Option (right to buy) Award $0 +27.5K $0.00 27.5K Dec 14, 2021 Common Stock 27.5K $2.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.